InMed Pharmaceuticals (INM) Net Cash Flow (2019 - 2026)

InMed Pharmaceuticals has reported Net Cash Flow for 8 years, with the latest figure at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 216.11% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $811547.0 (up 127.79% YoY), and the FY2025 full-year result was $4.5 million, up 292.42% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$1.5 million, up from -$2.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $6.4 million in Q2 2025, with the low at -$5.4 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$584314.2 across 5 years, with a median of -$1.5 million in 2026.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 849.58% — and 2025, when it soared 721.59%.
• InMed Pharmaceuticals' Net Cash Flow stood at $2.6 million in 2022, then sank by 171.02% to -$1.8 million in 2023, then declined by 17.07% to -$2.2 million in 2024, then declined by 9.83% to -$2.4 million in 2025, then jumped by 38.41% to -$1.5 million in 2026.
• The last three Net Cash Flow figures came in at -$1.5 million (Q1 2026), -$2.4 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.